GuidelineCurrent atherosclerosis reports2019
The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know.
Guideline in Current atherosclerosis reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Sociotechnical Intervention for Improved Delivery of Preventive Cardiovascular Care to Rural Communities: Participatory Design Approach.Journal of medical Internet research · 2022Trial
- Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets.Frontiers in medicine · 2026Review
- Recent insights into the pathophysiology and implications for surgery in atherosclerosis.Journal of cardiothoracic surgery · 2025Review
- The association of early pregnancy dyslipidemia with preterm birth in twin pregnancies: a retrospective cohort study.BMC pregnancy and childbirth · 2024Article
- Towards Optimal Cardiovascular Health: A Comprehensive Review of Preventive Strategies.Cureus · 2024Review
- Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies.Annals of medicine and surgery (2012) · 2024Review
- Effect of Urinary Albumin Creatinine Ratio on Cardiovascular Morbidity and Mortality in Diabetes Patients with Atherosclerotic Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance.Vascular health and risk management · 2022Review
- Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions.Current atherosclerosis reports · 2022Review
- Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.Cardiovascular drugs and therapy · 2021Review
- Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases.International journal of molecular sciences · 2021Review
- Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond.Current opinion in endocrinology, diabetes, and obesity · 2021Review
- Relationship of Noninvasive Assessment of Arterial Stiffness with 10-Year Atherosclerotic Cardiovascular Disease (ASCVD) Risk in a General Middle-Age and Elderly Population.International journal of general medicine · 2021Article
- Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session.Current atherosclerosis reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe 2018 ACC/AHA Multisociety blood cholesterol guidelines provide updated recommendations based on contemporary evidence on the management of serum cholesterol for the prevention of atherosclerotic cardiovascular disease (ASCVD) events. This review discusses clinically important topics in the new guidelines related to secondary ASCVD prevention. RECENT
findingsSince the 2013 ACC/AHA blood cholesterol guidelines, several large randomized control trials involving ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (evolocumab and alirocumab) have been published. The trials provided evidence that these non-statin, LDL-cholesterol lowering agents are efficacious in reducing risk for ASCVD events in patients with clinical ASCVD. The 2018 guidelines incorporate these new findings into updated clinical recommendations on therapeutic strategies related to the use of ezetimibe and PCSK9 inhibitors. The guidelines also recommend risk stratification of secondary prevention patients to identify those at very high-risk of ASCVD events as these patients would derive the most absolute risk reduction from the addition of non-statin therapies. While high-intensity statins remain the first-line treatment to prevent recurrent ASCVD events in secondary prevention patients, ezetimibe and PCSK9 inhibitors are evidence-based non-statin agents that can be used when residual on top of maximally tolerated statin therapy in patients deemed to be at very-high risk of recurrent ASCVD events.
Indexed as
Identifiers
30941517What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.